Mallinckrodt plc Reports First Quarter 2023 Financial Result

Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net...

Related Keywords

Ireland , United States , Dublin , Irish , American , Siggi Olafsson , Daniel Speciale , Derek Belz , Joele Frank , Michael Freitag , Wilkinson Brimmer Katcher , Aaron Palash , Community Interest , Us Drug Enforcement Administration , Revenue Service Under Section , Mallinckrodt Pharmaceuticals , Company Specialty Brands , Exchange Commission , Advanced Launch , Successful Uptake , Hospital Formulary Access , Continued Medical Community Interest , First Quarter Net Sales , Net Loss , Diluted Loss Per Share , Adjusted Diluted Earnings Per Share , Reduced Exposure , Demonstrating Ongoing Focus , Disciplined Balance Sheet , Webcast Today , Specialty Generics , Chief Executive , Specialty Brands , Coronavirus Aid , Economic Security , Call Participant Registration , Investor Relations , Private Securities Litigation Reform Act , Internal Revenue Service , Internal Revenue Code , Acthar Gel , Enforcement Administration , Financial Condition , Annual Report , Quarterly Reports , Corporate Controller , Chief Investor Relations , Wilkinson Brimmer , Related Litigation Settlement , Flows From Operating Activities , Flows From Investing Activities , Flows From Financing Activities , Mallinckrodt Plc ,